Company & Sponsor Intelligence
University of Oklahoma
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials3
Recruiting1
Completed2
Countries1
Therapeutic footprint
adhdstroke
Indexed studies
NCT00418262Open-Label Study of the Long Term Tolerability and Safety of Atomoxetine in Children With FASD and ADD/ADHD
adhd · United StatesPHASE3
adhd · United StatesPHASE3
NCT00417794Assess the Effectiveness of Atomoxetine in Children With Fetal Alcohol Syndrome and ADD/ADHD
adhd · United StatesPHASE1
adhd · United StatesPHASE1
NCT03980457Effects of Exoskeleton-Assisted Gait Training on Functional Rehabilitation Outcomes in Patients With Stroke
stroke · United StatesNA
stroke · United StatesNA
Intelligence layer updated: 2026-10-11 23:31:09.606883+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →